NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $6.16 -0.06 (-0.96%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$6.14 -0.03 (-0.41%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Entrada Therapeutics Stock (NASDAQ:TRDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$6.01▼$6.2550-Day Range$5.83▼$7.7852-Week Range$5.55▼$16.45Volume374,038 shsAverage Volume305,251 shsMarket Capitalization$239.87 millionP/E RatioN/ADividend YieldN/APrice Target$17.75Consensus RatingModerate Buy Company Overview Entrada Therapeutics, Inc. is a biotechnology company focused on developing medicines designed to address diseases caused by dysfunctional proteins inside cells. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic molecules into target cells and help them escape endosomes, cellular compartments that can limit the activity of certain treatments. Entrada is applying the EEV platform to oligonucleotide-based medicines, including compounds designed to modify RNA and influence the production of disease-associated proteins. Its development programs have included treatments for Duchenne muscular dystrophy (DMD), including exon-skipping candidates such as ENTR-601-44, as well as programs for myotonic dystrophy type 1 and other serious genetic diseases. Founded in 2016 and headquartered in Boston, Massachusetts, Entrada conducts research and clinical development primarily in the United States while pursuing collaborations and potential commercial opportunities in international markets. The company’s pipeline and partnerships are focused on advancing intracellular therapeutics for patients with limited treatment options.AI Generated. May Contain Errors. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 332nd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEntrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEntrada Therapeutics has a consensus price target of $17.75, representing about 188.1% upside from its current price of $6.16.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Entrada Therapeutics are expected to grow in the coming year, from ($4.03) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.79% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 8.06.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 16.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.57 News SentimentEntrada Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Entrada Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for TRDA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,725,291.00 in company stock.Percentage Held by Insiders9.49% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRDA Stock News HeadlinesEntrada Therapeutics (NASDAQ:TRDA) Stock Rating Cut to "Sell" at Wall Street Zen1 hour ago | americanbankingnews.comEntrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramSeptember 10, 2026 | finanznachrichten.deMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now. | TradeSmith (Ad)Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramSeptember 10, 2026 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 28,837 Shares of StockSeptember 10, 2026 | insidertrades.comInsider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in StockSeptember 4, 2026 | insidertrades.comInsider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in StockSeptember 1, 2026 | insidertrades.comInsider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in StockAugust 27, 2026 | insidertrades.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $10.28 at the beginning of the year. Since then, TRDA stock has decreased by 40.1% and is now trading at $6.16. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by $0.04. The company earned $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative trailing twelve-month return on equity of 57.61%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering on Thursday, October 28th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Top institutional shareholders of Entrada Therapeutics include 5AM Venture Management LLC (10.42%), BlackRock Inc. (6.65%), Wellington Management Group LLP (2.45%) and Nantahala Capital Management LLC (0.77%). Insiders that own company stock include Bros Advisors Lp Baker, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Ventures V LP 5Am, Kush Parmar, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim and Bernhardt G Zeiher. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/05/2026Today9/26/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TRDA's financial health is in the Red zone, according to TradeSmith. TRDA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees152Year Founded2016Price Target and Rating Average Price Target for Entrada Therapeutics$17.75 High Price Target$23.00 Low Price Target$11.00 Potential Upside/Downside+188.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.75 million Net Margins-3,537.73% Pretax Margin-3,520.25% Return on Equity-57.61% Return on Assets-46.54% Debt Debt-to-Equity RatioN/A Current Ratio10.89 Quick Ratio10.89 Sales & Book Value Annual Sales$25.42 million Price / Sales9.44 Cash FlowN/A Price / Cash FlowN/A Book Value$8.01 per share Price / Book0.77Miscellaneous Outstanding Shares38,940,000Free Float35,242,000Market Cap$239.87 million OptionableOptionable Beta-0.25 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:TRDA) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
